The specter of generic competition has repeatedly loomed above copyright’s blockbuster drug, PDE5 Inhibitor, triggering questions about the prospects of similar pharmaceutical holdings. While early periods saw substantial gains, the exclusivity expiration has allowed the way for cheaper substitutes, possibly diminishing revenue and creating a rea